作者: Aart J. van der Lely , Wouter W. de Herder , Eric P. Krenning , Dik J. Kwekkeboom
关键词:
摘要: With the in vivo demonstration of somatostatin-receptor-positive tumors patients using a radiolabeled somatostatin analog, peptide receptor scintigraphy became available some 15 yr ago. Octreoscan® is radiopharmaceutical with proven clinical importance visualization tumors, and overall sensitivity imaging high. In number neuroendocrine tumor types, as well Hodgkin’s disease, inclusion localization or staging procedure may be very rewarding. The value other like breast cancer, granulomatous diseases, has to established.